Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Manifestations and Outcomes of Older Patients with COVID-19: A Comprehensive Review

  • Jeong Eun Lee (Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine) ;
  • Da Hyun Kang (Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine) ;
  • So-Yun Kim (Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine) ;
  • Duk Ki Kim (Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine) ;
  • Song I Lee (Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine)
  • Received : 2023.10.03
  • Accepted : 2024.01.13
  • Published : 2024.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

The consequences of coronavirus disease 2019 (COVID-19) are particularly severe in older adults with a disproportionate number of severe and fatal outcomes. Therefore, this integrative review aimed to provide a comprehensive overview of the clinical characteristics, management approaches, and prognosis of older patients diagnosed with COVID-19. Common clinical presentations in older patients include fever, cough, and dyspnea. Additionally, preexisting comorbidities, especially diabetes and pulmonary and cardiovascular diseases, were frequently observed and associated with adverse outcomes. Management strategies varied, however, early diagnosis, vigilant monitoring, and multidisciplinary care were identified as key factors for enhancing patient outcomes. Nonetheless, the prognosis remains guarded for older patients, with increased rates of hospitalization, mechanical ventilation, and mortality. However, timely therapeutic interventions, especially antiviral and supportive treatments, have demonstrated some efficacy in mitigating the severe consequences in this age group. In conclusion, while older adults remain highly susceptible to severe outcomes from COVID-19, early intervention, rigorous monitoring, and comprehensive care can play a pivotal role in improving their clinical outcomes.

Keywords

References

  1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021;19:141-54. 
  2. World Health Organization. WHO coronavirus (COVID-19) dashboard [Internet]. Geneva: WHO; 2024 [cited 2024 Feb 21]. Available from: https://covid19.who.int/. 
  3. Krishnan A, Hamilton JP, Alqahtani SA, Woreta TA. COVID-19: an overview and a clinical update. World J Clin Cases 2021;9:8-23. 
  4. Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One 2021;16:e0247461. 
  5. Lim ZJ, Subramaniam A, Ponnapa Reddy M, Blecher G, Kadam U, Afroz A, et al. Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation: a meta-analysis. Am J Respir Crit Care Med 2021;203:54-66. 
  6. Ho FK, Petermann-Rocha F, Gray SR, Jani BD, Katikireddi SV, Niedzwiedz CL, et al. Is older age associated with COVID-19 mortality in the absence of other risk factors?: general population cohort study of 470,034 participants. PLoS One 2020;15:e0241824. 
  7. Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis 2021;21:855. 
  8. Kim L, Garg S, O'Halloran A, Whitaker M, Pham H, Anderson EJ, et al. Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET). Clin Infect Dis 2021;72:e206-14. 
  9. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146:110-8. 
  10. World Health Organization. WHO coronavirus (COVID-19) dashboard of Republic of Korea [Internet]. Geneva: WHO; 2024 [cited 2024 Feb 21]. Available from: https://covid19.who.int/region/wpro/country/kr. 
  11. Korea Centers for Disease Control & Prevention. Domestic occurrence status of COVID-19 [Internet]. Cheongju: KCDC; 2023 [cited 2024 Feb 21]. Available from: https://ncov.kdca.go.kr/bdBoardList_Real.do?brdId=1&brdGubun=11&ncvContSeq=&contSeq=&board_id=&gubun=. 
  12. Lithander FE, Neumann S, Tenison E, Lloyd K, Welsh TJ, Rodrigues JC, et al. COVID-19 in older people: a rapid clinical review. Age Ageing 2020;49:501-15. 
  13. Li P, Chen L, Liu Z, Pan J, Zhou D, Wang H, et al. Clinical features and short-term outcomes of elderly patients with COVID-19. Int J Infect Dis 2020;97:245-50. 
  14. Singhal S, Kumar P, Singh S, Saha S, Dey AB. Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis. BMC Geriatr 2021;21:321. 
  15. Niu S, Tian S, Lou J, Kang X, Zhang L, Lian H, et al. Clinical characteristics of older patients infected with COVID-19: a descriptive study. Arch Gerontol Geriatr 2020;89:104058. 
  16. Luo H, Liu S, Wang Y, Phillips-Howard PA, Ju S, Yang Y, et al. Age differences in clinical features and outcomes in patients with COVID-19, Jiangsu, China: a retrospective, multicentre cohort study. BMJ Open 2020;10:e039887. 
  17. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012;380:37-43. 
  18. Lee TW, Chung J, Song K, Kim E. Incidence and predictors of multimorbidity among older adults in Korea: a 10- year cohort study. BMC Geriatr 2022;22:565. 
  19. Seong GM, Baek AR, Baek MS, Kim WY, Kim JH, Lee BY, et al. Comparison of clinical characteristics and outcomes of younger and elderly patients with severe COVID-19 in Korea: a retrospective multicenter study. J Pers Med 2021;11:1258. 
  20. Wei C, Liu Y, Liu Y, Zhang K, Su D, Zhong M, et al. Clinical characteristics and manifestations in older patients with COVID-19. BMC Geriatr 2020;20:395. 
  21. Ibrahim ME, Al-Aklobi OS, Abomughaid MM, Al-Ghamdi MA. Epidemiological, clinical, and laboratory findings for patients of different age groups with confirmed coronavirus disease 2019 (COVID-19) in a hospital in Saudi Arabia. PLoS One 2021;16:e0250955. 
  22. Liu X, Lv J, Gan L, Zhang Y, Sun F, Meng B, et al. Comparative analysis of clinical characteristics, imaging and laboratory findings of different age groups with COVID-19. Indian J Med Microbiol 2020;38:87-93. 
  23. Martinez Chamorro E, Diez Tascon A, Ibanez Sanz L, Ossaba Velez S, Borruel Nacenta S. Radiologic diagnosis of patients with COVID-19. Radiologia (Engl Ed) 2021;63:56-73. 
  24. Statsenko Y, Al Zahmi F, Habuza T, Almansoori TM, Smetanina D, Simiyu GL, et al. Impact of age and sex on COVID-19 severity assessed from radiologic and clinical findings. Front Cell Infect Microbiol 2022;11:777070. 
  25. Sano T, Kimizuka Y, Fujikura Y, Hisada T, Watanabe C, Suematsu R, et al. COVID-19 in older adults: retrospective cohort study in a tertiary hospital in Japan. Geriatr Gerontol Int 2020;20:1044-9. 
  26. Guo T, Shen Q, Guo W, He W, Li J, Zhang Y, et al. Clinical characteristics of elderly patients with COVID-19 in Hunan Province, China: a multicenter, retrospective study. Gerontology 2020;66:467-75. 
  27. Geng MJ, Wang LP, Ren X, Yu JX, Chang ZR, Zheng CJ, et al. Risk factors for developing severe COVID-19 in China: an analysis of disease surveillance data. Infect Dis Poverty 2021;10:48. 
  28. Lee JY, Kim HA, Huh K, Hyun M, Rhee JY, Jang S, et al. Risk factors for mortality and respiratory support in elderly patients hospitalized with COVID-19 in Korea. J Korean Med Sci 2020;35:e223. 
  29. Briciu V, Topan A, Calin M, Dobrota R, Leucuta DC, Lupse M. Comparison of COVID-19 severity in vaccinated and unvaccinated patients during the Delta and Omicron wave of the pandemic in a Romanian tertiary infectious diseases hospital. Healthcare (Basel) 2023;11:373. 
  30. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ 2022;376:e069761. 
  31. Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, et al. Prediction models for diagnosis and prognosis of COVID-19: systematic review and critical appraisal. BMJ 2020;369:m1328. 
  32. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239-42. 
  33. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584:430-6. 
  34. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines [Internet]. Bethesda: NIH; 2024 [cited 2024 Feb 21]. Available from: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf. 
  35. Ma BH, Yip TC, Lui GC, Lai MS, Hui E, Wong VW, et al. Clinical outcomes following treatment for COVID-19 with nirmatrelvir/ritonavir and molnupiravir among patients living in nursing homes. JAMA Netw Open 2023;6:e2310887. 
  36. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, non-hospitalized adults with COVID-19. N Engl J Med 2022;386:1397-408. 
  37. Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis 2023;76:e342-9. 
  38. Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med 2022;386:305-15. 
  39. Basoulis D, Tsakanikas A, Gkoufa A, Bitsani A, Karamanakos G, Mastrogianni E, et al. Effectiveness of oral nirmatrelvir/ritonavir vs. intravenous three-day remdesivir in preventing progression to severe COVID-19: a single-center, prospective, comparative, real-life study. Viruses 2023;15:1515. 
  40. Mourad A, Thibault D, Holland TL, Yang S, Young AR, Arnold Egloff SA, et al. Dexamethasone for inpatients with COVID-19 in a national cohort. JAMA Netw Open 2023;6:e238516. 
  41. Grundeis F, Ansems K, Dahms K, Thieme V, Metzendorf MI, Skoetz N, et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev 2023;1:CD014962. 
  42. Margalit I, Tiseo G, Ripa M, Borghi V, Green H, Prendki V, et al. Real-life experience with remdesivir for treatment of COVID-19 among older adults: a multicentre retrospective study. J Antimicrob Chemother 2023;78:1505-9. 
  43. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021;384:693-704. 
  44. RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet 2022;400:359-68. 
  45. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med 2021;384:795-807. 
  46. Kyriakopoulos C, Ntritsos G, Gogali A, Milionis H, Evangelou E, Kostikas K. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: a systematic review and meta-analysis. Respirology 2021;26:1027-40. 
  47. Abizanda P, Calbo Mayo JM, Mas Romero M, Cortes Zamora EB, Tabernero Sahuquillo MT, Romero Rizos L, et al. Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia. J Am Geriatr Soc 2021;69:2752-8. 
  48. Korayem GB, Aljuhani O, Altebainawi AF, Shaya AI, Alnajjar LI, Alissa A, et al. The safety and effectiveness of tocilizumab in older adult critically ill patients with COVID-19: a multicenter, cohort study. Int J Infect Dis 2022;122:252-9. 
  49. Schulman S, Sholzberg M, Spyropoulos AC, Zarychanski R, Resnick HE, Bradbury CA, et al. ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost 2022;20:2214-25. 
  50. Cuker A, Tseng EK, Schunemann HJ, Angchaisuksiri P, Blair C, Dane K, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. Blood Adv 2022;6:4975-82. 
  51. Centers for Disease Control and Prevention. Overview of COVID-19 vaccines [Internet]. Atlanta: CDC; 2024 [cited 2024 Feb 21]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/overview-COVID-19-vaccines.html. 
  52. Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 2021;373:n1088. 
  53. Arregoces-Castillo L, Fernandez-Nino J, Rojas-Botero M, Palacios-Clavijo A, Galvis-Pedraza M, Rincon-Medrano L, et al. Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort. Lancet Healthy Longev 2022;3:e242-52. 
  54. Medeiros KS, Costa AP, Sarmento AC, Freitas CL, Goncalves AK. Side effects of COVID-19 vaccines: a systematic review and meta-analysis protocol of randomised trials. BMJ Open 2022;12:e050278. 
  55. Rosenblum HG, Hadler SC, Moulia D, Shimabukuro TT, Su JR, Tepper NK, et al. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices: United States, July 2021. MMWR Morb Mortal Wkly Rep 2021;70:1094-9. 
  56. Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices: United States, June 2021. MMWR Morb Mortal Wkly Rep 2021;70:977-82. 
  57. Yamamoto K. Adverse effects of COVID-19 vaccines and measures to prevent them. Virol J 2022;19:100. 
  58. Warkentin TE, Pai M. The epidemiology of thrombosis with thrombocytopenia syndrome: analogies with heparin-induced thrombocytopenia. Ann Intern Med 2022;175:604-5. 
  59. Romero Starke K, Reissig D, Petereit-Haack G, Schmauder S, Nienhaus A, Seidler A. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob Health 2021;6:e006434. 
  60. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19): United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69:343-6. 
  61. Yanez ND, Weiss NS, Romand JA, Treggiari MM. COVID-19 mortality risk for older men and women. BMC Public Health 2020;20:1742. 
  62. Casas-Deza D, Bernal-Monterde V, Aranda-Alonso AN, Montil-Miguel E, Julian-Gomara AB, Letona-Gimenez L, et al. Age-related mortality in 61,993 confirmed COVID-19 cases over three epidemic waves in Aragon, Spain. Implications for vaccination programmes. PLoS One 2021;16:e0261061. 
  63. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med 2020;180:1436-47. 
  64. Harris E. Most COVID-19 deaths worldwide were among older people. JAMA 2023;329:704. 
  65. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med 2020;180:1345-55. 
  66. Malhotra V, Basu S, Sharma N, Kumar S, Garg S, Dushyant K, et al. Outcomes among 10,314 hospitalized COVID-19 patients at a tertiary care government hospital in Delhi, India. J Med Virol 2021;93:4553-8. 
  67. Hoffmann C, Wolf E. Older age groups and country-specific case fatality rates of COVID-19 in Europe, USA and Canada. Infection 2021;49:111-6. 
  68. Kragholm K, Andersen MP, Gerds TA, Butt JH, Ostergaard L, Polcwiartek C, et al. Association between male sex and outcomes of coronavirus disease 2019 (COVID-19): a Danish nationwide, register-based study. Clin Infect Dis 2021;73:e4025-30. 
  69. Mayerhofer T, Klein S, Wernly B, Flaatten H, Guidet B, De Lange DW, et al. Diabetes mellitus is associated with 90-day mortality in old critically ill COVID-19 patients: a multicenter prospective observational cohort study. Infection 2023;51:1407-15. 
  70. Alves VP, Casemiro FG, Araujo BG, Lima MA, Oliveira RS, Fernandes FT, et al. Factors associated with mortality among elderly people in the COVID-19 pandemic (SAR-SCoV-2): a systematic review and meta-analysis. Int J Environ Res Public Health 2021;18:8008. 
  71. Trecarichi EM, Mazzitelli M, Serapide F, Pelle MC, Tassone B, Arrighi E, et al. Clinical characteristics and predictors of mortality associated with COVID-19 in elderly patients from a long-term care facility. Sci Rep 2020;10:20834. 
  72. Berenguer J, Borobia AM, Ryan P, Rodriguez-Bano J, Bellon JM, Jarrin I, et al. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. Thorax 2021;76:920-9. 
  73. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect 2020;80:639-45. 
  74. COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med 2021;47:60-73. 
  75. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect 2020;80:e14-8. 
  76. Gao S, Jiang F, Jin W, Shi Y, Yang L, Xia Y, et al. Risk factors influencing the prognosis of elderly patients infected with COVID-19: a clinical retrospective study in Wuhan, China. Aging (Albany NY) 2020;12:12504-16. 
  77. Bruno RR, Wernly B, Flaatten H, Fjolner J, Artigas A, Bollen Pinto B, et al. Lactate is associated with mortality in very old intensive care patients suffering from COVID-19: results from an international observational study of 2860 patients. Ann Intensive Care 2021;11:128. 
  78. Bavaro DF, Diella L, Fabrizio C, Sulpasso R, Bottalico IF, Calamo A, et al. Peculiar clinical presentation of COVID-19 and predictors of mortality in the elderly: a multicentre retrospective cohort study. Int J Infect Dis 2021;105:709-15. 
  79. Ko RE, Moon SM, Kang D, Cho J, Chung CR, Lee Y, et al. Translation and validation of the Korean version of the clinical frailty scale in older patients. BMC Geriatr 2021;21:47. 
  80. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676-82. 
  81. Aw D, Woodrow L, Ogliari G, Harwood R. Association of frailty with mortality in older inpatients with COVID-19: a cohort study. Age Ageing 2020;49:915-22. 
  82. Pranata R, Henrina J, Lim MA, Lawrensia S, Yonas E, Vania R, et al. Clinical frailty scale and mortality in COVID-19: a systematic review and dose-response meta-analysis. Arch Gerontol Geriatr 2021;93:104324. 
  83. Owen RK, Conroy SP, Taub N, Jones W, Bryden D, Pareek M, et al. Comparing associations between frailty and mortality in hospitalised older adults with or without COVID-19 infection: a retrospective observational study using electronic health records. Age Ageing 2021;50:307-16. 
  84. Jung C, Flaatten H, Fjolner J, Bruno RR, Wernly B, Artigas A, et al. The impact of frailty on survival in elderly intensive care patients with COVID-19: the COVIP study. Crit Care 2021;25:149. 
  85. Kim Y, Bitna-Ha, Kim SW, Chang HH, Kwon KT, Bae S, et al. Post-acute COVID-19 syndrome in patients after 12 months from COVID-19 infection in Korea. BMC Infect Dis 2022;22:93. 
  86. Korea Disease Control and Prevention Agency. COVID-19, long COVID [Internet]. Cheongju: KDCA; 2023 [cited 2024 Feb 21]. Available from: https://ncv.kdca.go.kr/pot/www/CVID19/CVID19_INFO/COVID_SNDRM.jsp#. 
  87. Parker AM, Brigham E, Connolly B, McPeake J, Agranovich AV, Kenes MT, et al. Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care. Lancet Respir Med 2021;9:1328-41. 
  88. Global Burden of Disease Long COVID Collaborators; Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 2022;328:1604-15. 
  89. Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers [Internet]. Atlanta: CDC; 2024 [cited 2024 Feb 21]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html. 
  90. Yelin D, Moschopoulos CD, Margalit I, Gkrania-Klotsas E, Landi F, Stahl JP, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect 2022;28:955-72. 
  91. Halpin S, O'Connor R, Sivan M. Long COVID and chronic COVID syndromes. J Med Virol 2021;93:1242-3. 
  92. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022;22:e102-7. 
  93. COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE); 2020. 
  94. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute COVID-19 in primary care. BMJ 2020;370:m3026. 
  95. Mansell V, Hall Dykgraaf S, Kidd M, Goodyear-Smith F. Long COVID and older people. Lancet Healthy Longev 2022;3:e849-54. 
  96. Fung KW, Baye F, Baik SH, Zheng Z, McDonald CJ. Prevalence and characteristics of long COVID in elderly patients: an observational cohort study of over 2 million adults in the US. PLoS Med 2023;20:e1004194.